Sera Prognostics

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sera Prognostics reports revenue growth and innovation drive amidst challenges

Sera Prognostics demonstrated strong financial performance with revenue growth and reduced net loss in Q4 2022.
The company's focus on innovation, new data, and upcoming studies positions it well for future growth and market success.
Challenges in revenue expectations and payer dynamics require strategic navigation, but opportunities from studies and technology advancements are promising.

Sera Prognostics reports robust Q1 performance amidst revenue challenges

Sera Prognostics demonstrated strong performance in Q1 2023 with notable revenue growth and positive trial outcomes, showcasing its research capabilities and commitment to innovation.
While facing challenges in revenue projections and financial losses, the company's strategic focus on cost efficiency and strong cash reserves provide a foundation for future growth.
Opportunities lie in upcoming study analyses, continued research efforts, and potential partnerships, positioning Sera Prognostics for sustainable development and market expansion.

Sera Prognostics reports stable Q2 revenue, eyes growth opportunities

Sera Prognostics demonstrated stable financial performance in Q2 2023, with a focus on revenue growth and cost management.
The company's PreTRM test showed promising results in reducing neonatal length of stay, enhancing its market position.
While facing challenges in commercialization and global scaling, Sera has opportunities to expand revenue streams and strengthen partnerships.

SERA reports Q3 revenue growth, focuses on expense management

SERA's financials show revenue growth potential with a focus on expense management
Balancing product development and study outcomes crucial for future success
Strategic steps taken to ensure operational sustainability and revenue growth

Sera Prognostics reports positive study outcomes amidst financial challenges

Sera Prognostics demonstrated positive study outcomes with potential for improved neonatal health, despite a net loss in Q4 2023.
Strategic focus on managing expenses, leveraging study results, and achieving key milestones for future revenue growth.
Opportunities lie in lower cash expenses for 2024, revenue growth initiatives, and the launch of a blood sample self-collection device.
Challenges include balancing financial performance, cash management, and addressing analyst inquiries.

Sera Prognostics reports improved Q1 financials and eyes global expansion

Sera Prognostics made strides in financial performance and operational efficiency in Q1 2024.
The company's focus on expanding test adoption and improving margins shows promise for growth.
Despite challenges like regulatory impacts, Sera Prognostics is poised for strategic investments and market expansion.

Sera Prognostics reports Q2 revenue decline, focuses on growth strategies

Sera Prognostics navigated challenges with decreased revenue and a net loss in Q2 2024, emphasizing cost management and efficiency.
The company's strengths lie in strategic progress, enhanced market visibility, and new market opportunities with the PreTRM Test approval.
Opportunities exist in leveraging study results for product adoption, expanding market reach through awareness initiatives, and utilizing financial flexibility for growth.

Sera Prognostics focuses on combating premature births, strengthens revenue growth

Sera Prognostics is actively working to combat premature birth risks in the U.S.
Despite financial challenges, the company maintains a solid cash position for growth
Strategic initiatives aim to increase revenue and awareness for sustainable progress

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2021.

Sera Prognostics Reports Second Quarter 2021 Financial Results

SALT LAKE CITY, July 14, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its initial public offering of 4,687,500 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to Sera from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75.0 million. The shares are expected to begin trading on the Nasdaq Global Market on July 15, 2021 under the symbol “SERA.” The offering is expected to close on July 19, 2021, subject to customary closing conditions. In addition, Sera has granted the underwriters a 30-day option to purchase up to an additional 703,125 shares of common stock at the initial price to the public less underwriting discounts.

Sera Prognostics Announces Pricing of Initial Public Offering

News for Sera Prognostics Stock (SERA)